VSTM

Verastem, Inc.

6.55 USD

Last updated Nov 28, 13:52 UTC

Yesterday HIGH

$6.85

Yesterday LOW

$6.5

52w HIGH

$15.19

52w LOW

$3.87

EPS

-0.71

PE

-9.23

Next Earnings

Mar 12, 2024

Overview News Government Trades

Verastem, Inc. stock is up 5.31% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 11 November’s closed higher than October. 100% of analysts rate it a buy.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Needham, United States Of America

Website

verastem.com

richadhand@benzinga.com

Mon Jul 3, 2023

RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $34

RBC Capital analyst Gregory Renza maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $36 to $34.
richadhand@benzinga.com

Tue Jun 27, 2023

Truist Securities Reiterates Buy on Verastem, Maintains $60 Price Target

Truist Securities analyst Srikripa Devarakonda reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $60 price target.
richadhand@benzinga.com

Fri Jun 23, 2023

Truist Securities Reiterates Buy on Verastem, Maintains $60 Price Target

Truist Securities analyst Srikripa Devarakonda reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $60 price target.
Lisa Levin

Fri Jun 16, 2023

Why Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket

Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) shares gained 192.8% to $0.2427 in pre-market trading. Evelo Biosciences was granted U.S. patent #11672834 for "Prebiotic Compositions And Methods Of Use Thereof For Modulation Of The Microbiome."
Benzinga Newsdesk

Fri Jun 16, 2023

Verastem Oncology shares are trading lower after the company priced its public offering of 7.2M shares at $9.75/share and pre funded warrants to purchase up to 1.5M shares at $9.749/warrant.
Benzinga Newsdesk

Fri Jun 16, 2023

Verastem Oncology Priced Its Underwritten Public Offering Of 7.18M Shares At $9.75/Share And Pre-funded Warrants To Purchase Up To 1.54M Shares At $9.749 Per Pre-funded Warrant, With Gross Proceeds Of Approximately $85M
Benzinga Newsdesk

Thu Jun 15, 2023

Verastem Oncology Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants; No Terms Disclosed

Verastem Oncology, (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and pre-funded
Lisa Levin

Thu Jun 15, 2023

Crude Oil Rises Sharply; Jabil Posts Upbeat Q3 Results

U.S. stocks traded higher toward the end of trading, with Dow Jones gaining around 450 points on Thursday. The Dow traded up 1.32% to 34,429.39 while the NASDAQ rose 1.27% to 13,799.28. The S&P 500, also rose, gaining, 1.31% to 4,429.89.
Vandana Singh

Thu Jun 15, 2023

Verastem's Ovarian Cancer Drug Showing Promise, Analyst Upgrades Stock

Mizuho Securities has upgraded Verastem Inc (NASDAQ: VSTM) from Neutral to Buy with a price target of $36, up from $24, to
Benzinga Insights

Thu Jun 15, 2023

12 Health Care Stocks Moving In Thursday's Intraday Session

BTIG

Tue Nov 21, 08:34

buy

initial
Truist Securities

Wed Nov 15, 11:55

buy

confirm